- 期刊
Pembrolizumab和Ipilimumab用在卵巢癌治療的檢視
The role of pembrolizumab and ipilimumab for the treatment of ovarian cancer
摘要
卵巢癌是婦癌死亡率最高的一種疾病，手術是最佳治療方法，先進行減積手術切除灶，再輔以carboplatin和palcitaxel化學治療。近來，由於免疫治療的發展，使用免疫檢查點抑制劑pembrolizumab和抗細胞毒性T淋巴球相關蛋白ipilimumab，對卵巢癌有革新的治療。然仍有待更大規模的研究，始能瞭解合併使用免疫檢查點和CTLA-4抑制劑在臨床上治療卵巢癌的效果。
並列摘要
Ovarian cancer is one of the most lethal gynecological tumors. Surgery is the optimal treatment for the ovarian cancer, whereas carboplatin and paclitaxel chemotherapy followed by debulking surgery is the standard therapy for advanced ovarian cancer. Leveraging the immune system through the use of immune checkpoint inhibitors pembrolizumab and anti-cytotoxic T lymphocyte-associated protein ipilimumab presents a profound opportunity to revolutionize ovarian cancer treatment. Further studies are need to better define the prognostic role in the combination of immune checkpoint and CTLA-4 inhibitor, to identify predictors of response and the optimal clinical setting in ovarian cancer.